Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

Medicine and Dentistry

• Crohn's Disease 100%
• Ulcerative Colitis 70%
• Patient 70%
• Tofacitinib 50%
• Ustekinumab 50%
• Tumor Necrosis Factor 40%
• Combination Therapy 30%
• Spontaneous Remission 30%
• Patient with Ulcerative Colitis 30%
• Therapeutic Procedure 30%
• Inpatient 20%
• Biological Product 10%
• Inflammatory Bowel Disease 10%
• Group Therapy 10%
• Chemotherapeutic Agent 10%
• Drug 10%
• Biological Therapy 10%
• TNF Inhibitor 10%
• Recurrence Risk 10%
• Relapse 10%